We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

98 hedge funds and large institutions have $79.5M invested in CytomX Therapeutics in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 28 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 28

12.42% less ownership

Funds ownership: 82.07% → 69.65% (-12%)

18% less funds holding

Funds holding: 119 → 98 (-21)

45% less capital invested

Capital invested by funds: $143M → $79.5M (-$63.8M)

48% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 40

Holders
98
Holders Change
-21
Holders Change %
-17.65%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
26
Reduced
28
Closed
40
Calls
$37K
Puts
–
Net Calls
+$37K
Net Calls Change
+$8K

Top Buyers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
+$2.43M
2
NM
Newtyn Management
New York
+$2.06M
3
TCM
Tang Capital Management
California
+$2.02M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.83M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.07M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$6.06M
2
RI
RTW Investments
New York
-$5.61M
3
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$3.45M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.1M
5
State Street
State Street
Massachusetts
-$1.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$10.6M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$9.29M -$277K -144,499 -3%
RI
3
RTW Investments
New York
$5.21M -$5.61M -2,929,993 -51%
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$5.03M -$3.1M -1,621,300 -37%
RCMNY
5
Rubric Capital Management (New York)
New York
$4.4M – – –
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$3.66M – – –
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$3.37M +$1.83M +954,119 +108%
BlackRock
8
BlackRock
New York
$3.34M -$6.06M -3,165,503 -63%
CS
9
Candriam SCA
Luxembourg
$3.03M – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$2.66M +$1.07M +558,361 +62%
Millennium Management
11
Millennium Management
New York
$2.64M -$1.54M -803,458 -36%
LCM
12
Laurion Capital Management
New York
$2.33M +$2.43M +1,270,900 New
PIM
13
Platinum Investment Management
Australia
$2.25M +$478K +249,460 +25%
NM
14
Newtyn Management
New York
$1.96M +$2.06M +1,073,400 New
TCM
15
Tang Capital Management
California
$1.93M +$2.02M +1,054,673 New
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$1.64M -$342K -178,661 -17%
Fidelity Investments
17
Fidelity Investments
Massachusetts
$1.29M +$2.67K +1,392 +0.2%
PAMS
18
Pictet Asset Management (Switzerland)
Switzerland
$1.21M +$588K +307,380 +87%
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$1.16M -$52.9K -27,645 -4%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$1.07M -$894K -467,083 -44%
OMC
21
Oasis Management Company
Cayman Islands
$989K +$1.03M +540,541 New
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$727K -$789K -411,899 -51%
AQR Capital Management
23
AQR Capital Management
Connecticut
$717K +$750K +391,860 New
Two Sigma Advisers
24
Two Sigma Advisers
New York
$708K +$74.1K +38,700 +11%
Citadel Advisors
25
Citadel Advisors
Florida
$615K +$616K +321,607 +2,236%
1
2 3 4 5

CTMX Hedge Fund Activity: Q2 2022 in Review

98 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2022, worth a combined $79.5M — down 45% from $143M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of CTMX and 21 opened new positions — a net loss of 19 holders — while 28 trimmed existing stakes and 26 added.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $2.43M. The largest seller was BlackRock, cutting an estimated $6.06M.

  • 98 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2022, down from 119 in Q1 2022.
  • Funds reported $79.5M of CytomX Therapeutics stock for Q2 2022, down 45% quarter-over-quarter.
  • 21 funds opened new CytomX Therapeutics positions in Q2 2022 and 40 closed out, a net change of -19 holders.
  • The largest CytomX Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $2.43M added.
  • The largest CytomX Therapeutics seller in Q2 2022 was BlackRock, an estimated $6.06M sold.

Based on aggregated 13F filings for Q2 2022.